Comparative Pharmacology
Head-to-head clinical analysis: ORAP versus PROLIXIN ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORAP versus PROLIXIN ENANTHATE.
ORAP vs PROLIXIN ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orap (pimozide) is a diphenylbutylpiperidine antipsychotic that selectively blocks dopamine D2 receptors in the central nervous system, with weak antagonism at alpha1-adrenergic and H1-histamine receptors. Its anti-dyskinetic effect in Tourette syndrome may also involve blockade of calcium channels.
Fluphenazine (the active entity of PROLIXIN ENANTHATE) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic and mesocortical pathways. It also exhibits alpha-adrenergic blocking and anticholinergic effects.
Initial: 2 mg orally twice daily; maintenance: 2-10 mg twice daily. Maximum 20 mg/day.
12.5-50 mg intramuscularly every 1-3 weeks. Initial dose: 2.5-12.5 mg IM as a test dose; gradual titration based on response and tolerability.
None Documented
None Documented
Clinical Note
moderateVorapaxar + Tranilast
"Vorapaxar may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateVorapaxar + Resveratrol
"Vorapaxar may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateVorapaxar + Nimesulide
"Vorapaxar may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateVorapaxar + Epoprostenol
"Vorapaxar may increase the antiplatelet activities of Epoprostenol."
Terminal elimination half-life is 20–40 hours (mean 27 hours). Steady-state achieved in 4–7 days.
Terminal elimination half-life approximately 11-15 days due to slow release from intramuscular depot; requires monitoring for prolonged effects after discontinuation
Primarily hepatic metabolism; approximately 40% excreted in urine as metabolites, 15% in feces as unchanged drug and metabolites.
Primarily renal (30-40% as metabolites, <1% unchanged) and biliary/fecal (15-20%)
Category C
Category C
Antipsychotic
Antipsychotic